Florbetaben for Imaging of Vascular Amyloid

Status Recruiting

Clinical Trial Summary

The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.

Clinical Trial Description

The Primary Objective is to determine the feasibility of using 18F-Florbetaben PET in patients with recent ACS or stroke/TIA to detect inflammatory plaque. Exploratory Objectives will define relationships of calcification imaging to other biomarkers and comparisons between high and low plaque burden regions and between patients with and without recent vascular events. Patients with a recent ACS (i.e. STEMI or NSTEMI), stroke or transient ischemic attack (TIA) will be recruited will be recruited to the FERMATA study. A control population of patients with known vascular disease but without recent ACS, stroke/TIA will also be recruited. FERMATA is a pilot, single- centerre, imaging study. We will evaluate the ability of the amyloid tracer, 18F-Florbetaben, to detect active atherosclerotic plaque in patients with recent ACS, or recent TIA/stroke. We plan to enroll 24 patients with ACS or patients with stroke/TIA and 6 control patients without recent ACS or stroke/TIA. Primary endpoint is the difference in Florbetaben uptake between the culprit artery (of either the ACS or TIA/stroke, respectively), and the non-culprit arteries. Parameters of interest are the maximal and total standard uptake values (SUVs) and tissue-to- background ratios (TBRs) of the coronary and carotid arteries as well as aorta. Exploratory endpoints include a correlation analysis (Pearson correlation) to evaluate the relationship of inflammation on Florbetaben PET/CT to the histopathological levels of inflammation. In addition, we will look to see if Florbetaben uptake on PET correlates with lesion levels of B-amyloid. Comparisons will also be made between regions of high plaque burden vs lower plaque burden and between patients with recent vascular events vs those who have not had recent events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06091319
Study type	Observational
Source	Ottawa Heart Institute Research Corporation
Contact	Kevin E Boczar, MD
Phone	6132821835
Email	kboczar@ottawaheart.ca
Status	Recruiting
Phase
Start date	October 9, 2023
Completion date	August 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04043052` - Mobile Technologies and Post-stroke Depression	N/A
Recruiting	`NCT03869138` - Alternative Therapies for Improving Physical Function in Individuals With Stroke	N/A
Completed	`NCT04101695` - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects	N/A
Completed	`NCT04034069` - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial	N/A
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Completed	`NCT00391378` - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)	N/A
Recruiting	`NCT06204744` - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial	N/A
Active, not recruiting	`NCT06043167` - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting	`NCT04535479` - Dry Needling for Spasticity in Stroke	N/A
Completed	`NCT03985761` - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke	N/A
Recruiting	`NCT00859885` - International PFO Consortium	N/A
Recruiting	`NCT06034119` - Effects of Voluntary Adjustments During Walking in Participants Post-stroke	N/A
Completed	`NCT03622411` - Tablet-based Aphasia Therapy in the Chronic Phase	N/A
Completed	`NCT01662960` - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke	N/A
Recruiting	`NCT05854485` - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke	N/A
Active, not recruiting	`NCT05520528` - Impact of Group Participation on Adults With Aphasia	N/A
Completed	`NCT03366129` - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Completed	`NCT05805748` - Serious Game Therapy in Neglect Patients	N/A
Recruiting	`NCT05621980` - Finger Movement Training After Stroke	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Florbetaben for Imaging of Vascular Amyloid — FERMATA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms